U.S. Markets closed

Merck to buy Tilos Therapeutics in deal valued at up to $773 million

John George
Merck to buy Tilos Therapeutics in deal valued at up to $773 million

Merck & Co. Inc, in its second megadeal involving a cancer therapy developer in as many months, entered into a definitive agreement Monday to acquire Tilos Therapeutics in a transaction valued up to $773 million. Tilos, based in Lexington, Mass., is a biopharmaceutical company that has developed a portfolio of new drug candidates that employ a novel approach to modulating the potent signaling molecule known as TGFβ. Tilos is developing treatments not only for cancer, but also for fibrosis and autoimmune disorders.